Use of anticoagulation at the time of discharge in patients with heart failure and atrial fibrillation

被引:7
|
作者
Pérez, IM
García, JM
Castroseiros, EF
Castelo, AG
Castro-Beiras, A
机构
[1] Complejo Hosp Univ Juan Canalejo, Serv Cardiol, Area Corzaon, La Coruna, Spain
[2] Univ A Coruna, Inst Ciencias Salud, La Coruna, Spain
[3] Complejo Hosp Cristal Pinor, Serv Cardiol, Orense, Spain
[4] Complejo Hosp Xeral Calde, Serv Cardiol, Lugo, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2003年 / 56卷 / 09期
关键词
anticoagulants; atrial fibrillation; heart failure;
D O I
10.1016/S0300-8932(03)76976-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives. To assess the degree of compliance with current guidelines for chronic anticoagulation in patients with heart failure and atrial fibrillation. Patients and method. From the INCARGAL Study database, we analyzed data from 195 consecutive patients (88 men; mean age 76 +/- 10 years) with both conditions, admitted to three Galician hospitals between January and March 1999. It was assumed that these patients should have received anticoagulant therapy at discharge, unless contraindicated. We studied the association of treatment at discharge (anticoagulation or not) with the presence or absence of contraindications. Results. 152 patients (78%) had no contraindication for anticoagulation and 43 had at least one (absolute: 11, relative: 32). Only 50% of patients without contraindications received anticoagulation at the time of discharge. No patient with an absolute contra indication and 3 with a relative one received anticoagulation. Factors related with the less frequent prescription of anticoagulation therapy in patients without a formal contraindication were: age, a previous history of coronary heart disease, absence of valvular heart disease, prior myocardial infarction, treatment with beta-blocking agents, non performance of an echocardiogram, and admission to a department other than cardiology. On multivariate analysis, age, prior myocardial infarction, and non-valvular disease were found to be independent predictors of less use of anticoagulation. Conclusions. Anticoagulant therapy is used less often than recommended at discharge in patients with heart failure and atrial fibrillation for whom there were no contraindications. Advanced age reduces its use. The presence of other indications for antiplatelet or anticoagulation therapy appears to determine the choice of one or the other. Noncompliance with the guidelines due to overprescription was not found.
引用
收藏
页码:880 / 887
页数:8
相关论文
共 50 条
  • [31] Oral anticoagulation in heart failure complicated by atrial fibrillation in routine data
    Moeckel, M.
    Baberg, H. T.
    Dirschedl, P.
    Levenson, B.
    Malzahn, J.
    Mansky, T.
    Guenster, C. H.
    Jeschke, E.
    EUROPEAN HEART JOURNAL, 2018, 39 : 679 - 679
  • [32] Racial Differences in Patient Characteristics and Oral Anticoagulation Use at Discharge Among Patients With Atrial Fibrillation
    Thomas, Kevin L.
    James, Roberta A.
    Marcsisin, Victoria
    Bimal, Shah R.
    Fermann, Gregory J.
    Fermann, Gregory J.
    Mashni, Susan M.
    Streiff, Michael B.
    Hylek, Elaine M.
    Granger, Christopher B.
    CIRCULATION, 2017, 136
  • [33] Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice
    Boos, Christopher J.
    Brown, Louise
    CURRENT OPINION IN CARDIOLOGY, 2016, 31 (02) : 229 - 234
  • [34] Impact of Heart Failure Type on Thromboembolic and Bleeding Risk in Patients With Atrial Fibrillation on Oral Anticoagulation
    Mentias, Amgad
    Briasoulis, Alexandros
    Shantha, Ghanshyam
    Alvarez, Paulino
    Vaughan-Sarrazin, Mary
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 123 (10): : 1649 - 1653
  • [35] Longitudinal changes in renal function in heart failure patients receiving oral anticoagulation for atrial fibrillation
    Giovinazzo, Stefano
    Carmisciano, Luca
    Toma, Matteo
    Rizzola, Ginevra
    La Malfa, Giovanni
    Sormani, Maria Pia
    Canepa, Marco
    Ameri, Pietro
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J130 - J131
  • [36] Effect of Heart Failure Type on Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulation
    Mentias, Amgad
    Palamaner, Ghanshyam
    Briasoulis, Alexandros
    Alvarez, Paulino
    Vaughan-Sarrazin, Mary
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S62 - S63
  • [37] Longitudinal changes in serum creatinine in patients with heart failure receiving oral anticoagulation for atrial fibrillation
    Giovinazzo, S.
    Toma, M.
    Ghigliotti, G.
    Chiarella, F.
    Brunelli, C.
    Porto, I.
    Canepa, M.
    Ameri, P. Pietro
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 533 - 534
  • [38] Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
    Fradley, Michael G.
    Ellenberg, Kerry
    Alomar, Mohammed
    Swanson, Justin
    Kharod, Anant
    Nguyen, Anh Thy H.
    Khodor, Sara
    Mishra, Shreya
    Duong, Linh M.
    Shah, Nirav
    Armanious, Merna
    Rhea, Isaac B.
    Schabath, Matthew B.
    Kip, Kevin E.
    JACC: CARDIOONCOLOGY, 2020, 2 (05): : 747 - 754
  • [39] PATTERNS OF ANTICOAGULATION USE IN CANCER PATIENTS WITH ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
    Fradley, Michael
    Ellenberg, Kerry
    Swanson, Justin
    Kharod, Anant
    Nguyen, Anh Thy H.
    Khodor, Sara
    Mishra, Shreya
    Duong, Linh M.
    Shah, Nirav
    Armanious, Merna
    Rhea, Isaac
    Schabath, Matthew
    Kip, Kevin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 504 - 504
  • [40] Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves
    Bottino, Roberta
    Carbone, Andreina
    Liccardo, Biagio
    Imbalzano, Egidio
    D'Andrea, Antonello
    Russo, Vincenzo
    KARDIOLOGIA POLSKA, 2022, 80 (02) : 137 - 150